2023-04-16 20:45:22
The first new antibiotic in Britain in more than 20 years is set to be approved, and is capable of treating bladder and urinary tract infections, following a groundbreaking study found the drug to be highly effective. The drug, called gebutidacin, outperformed one of the common antibiotics currently used to treat patients with infections, curing more than half of the participants who took it.
GSK, the pharmaceutical company that developed the drug, is in discussions with medical regulators in the UK regarding gibbutidacin for treating patients with drug-resistant UTIs.
related topics
Dozens of people in the UK have already received the treatment as part of a global trial, the results of which were presented on Friday at a scientific conference in Copenhagen.
“This drug offers hope to patients with recurrent UTIs who need new treatment,” says Dr. Aruni Muljirigama, from GSK, the drug’s developer. The data shows that this drug helps people who are most at risk of developing these infections.”
chronic infections
In Britain alone, there are regarding 1.7 million people – the majority of them women – who suffer from chronic urinary tract infections, which are classified as three or more infections per year.
In older patients, the infection can cause a dementia-like condition called delirium. There is also a risk of sepsis, which causes regarding 50,000 deaths annually.
While there are a number of antibiotics that can treat UTIs, over time these medications have become less effective because bacteria are able to build up resistance to the antibiotics.
Developing new antibiotics is time-consuming and expensive, and many big pharma companies no longer invest in antibiotic research. This means that despite the growing threat from resistant germs, no new antibiotic has been developed in more than two decades.
However, gebutidacin might soon change the rules, as new data shows that more than 50 percent of patients who were given the drug cured their UTIs. By comparison, nitrofurantoin, an antibiotic commonly used in the urinary tract, clears infection in 47 percent of patients.
Experiment results
The trial showed that gebutidacin is effective once morest drug-resistant forms of Escherichia coli, the most common bug that causes UTIs.
It has also been successful in treating patients with a history of recurrent UTIs, as well as those over the age of 50, who are at increased risk of severe UTI symptoms.
Experts believe that “gibutidacin” might benefit thousands, and Dr. Kat Anderson, a general practitioner who specializes in women’s health, says: “It’s great news, as it has proven to be a useful new treatment for fighting urinary tract infections,” adding, “We have waited a long time for an antibiotic.” new”.
important information
► A groundbreaking study revealed that «jibutidacin» is very effective .. and will change the rules of the game
► Existing antibiotics are becoming less effective because bacteria are able to resist
► Developing new antibiotics takes a long time and is financially costly
► Many major pharmaceutical companies are no longer investing in antibiotic research
► Experts: The drug is a new hope for patients with recurrent UTIs
Responsibility for the news: Cedar News is not responsible for this news in form or content, and it only expresses the point of view of its source or writer.
1681714718
#antibiotic #years
